Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Authors||Daniel J. DeAngelo, MD, PhD, Albert Thomas Quiery, MD, Deepti Radia, MD, Mark W Drummond, MB ChB, PhD, FRCPath, Jason Gotlib, MD, William A Robinson, MD, PhD, Elizabeth Hexner, MD, MS, Srdan Verstovsek, MD, PhD, Hongliang Shi, et al.|
|Title||2 Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)|
|Abstract Text||ASH Annual Meeting, Dec 2017, Plenary 2|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT D816V||mast cell neoplasm||predicted - sensitive||Avapritinib||Phase I||Actionable||In a Phase I trial, patients with either aggressive systemic mastocytosis, mast cell leukemia, or systemic mastocytosis with an associated hematologic neoplasm harboring KIT D816V demonstrated a reduction in mast cell burden and a decrease in KIT D816V allelic fraction when treated with Ayvakit (avapritinib) (ASH Annual Meeting, Dec 2017, Plenary 2).||detail...|